Tosi S, Marchesoni A, Messina K, Bellintani C, Sironi G, Faravelli C
Drugs Exp Clin Res. 1987;13(1):37-42.
The efficacy of captopril in the treatment of Raynaud's phenomenon was observed in an open study in 53 patients with primitive Raynaud's disease and in 18 patients with Raynaud's associated with scleroderma. Each patient was given captopril 25 mg three times a day for three months. The drug significantly decreased the frequency and the severity of ischaemic attacks in patients with Raynaud's disease, but did not affect the attacks in patients with scleroderma. These subjective ratings were supported by the results of digital strain gauge plethysmography during cold challenge. The therapy was discontinued in six patients (one because of an allergic skin reaction and five owing to orthostatic hypotension), but no serious side-effects were noticed.
在一项开放性研究中，观察了卡托普利对53例原发性雷诺病患者和18例硬皮病相关雷诺现象患者的治疗效果。每位患者每天服用3次25毫克卡托普利，持续3个月。该药物显著降低了雷诺病患者缺血性发作的频率和严重程度，但对硬皮病患者的发作没有影响。这些主观评分得到了冷激发试验期间数字应变仪体积描记法结果的支持。6例患者停止了治疗（1例因皮肤过敏反应，5例因体位性低血压），但未发现严重副作用。
